Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Theravac in Advanced Metastatic Melanoma
NCT01331915Phase 2Unknown
- Start
- Sep 2010
- Primary completion
- Oct 2013
- Modality
- Antibody Conjugates, Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of Theravac in melanoma (3 cohorts). Primary endpoints: Safety and toxicity of increasing doses of Theravac at 3 months and Detectable immune response at 24 weeks. Status: unknown.
02
Drugs
Theravac
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01331915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01331915.